Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCD Partnership

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

Novo Nordisk opens insulin facility in Russia

It will focus on new modern insulin formulation and filling

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

FDA starts review of Novo’s refiled diabetes pair

Tresiba and Ryzodeg were rejected in 2013

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

It’s time to get diabetes right

Patients should have access to the right treatment and care, at the right time, says the ABPI Pharmaceutical Diabetes Initiative 

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

- PMLiVE

AZ links with Harvard for diabetes research

Firm extends ties with the highly respected academic institution in hope of finding innovative leads

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links